Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Capecitabine in Advanced Head and Neck Cancer
NCT00266279Phase 2Completed
- Sponsor
- University of Louisville
- Start
- Apr 2005
- Primary completion
- Oct 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Louisville. Primary endpoint: Overall Response Rate. Started Apr 2005; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00266279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266279.